SCHEMBL321822

SCHEMBL321822

CC1(CO)CCNCC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL322166 0.97 EPHX1 (0.40)
SCHEMBL26667345 0.91 SLC6A2 (0.37)
SCHEMBL727929 0.84
SCHEMBL19045055 0.84
SCHEMBL19045058 0.84
Hydrochloric Acid SCHEMBL321968 0.82
Hydrochloric Acid SCHEMBL30282654 0.82
Trifluoroacetic Acid SCHEMBL2904301 0.82 HRH4 (0.35)
SCHEMBL5955637 0.79 KDM4E (0.30)
Ethoxycarbonyl Group SCHEMBL27746585 0.79 OPRM1 (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 202 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3672952-B1 BENZIMIDAZOLE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 EP claimed
EP-3661941-B1 THIAZOLOPYRIDINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2022-12-14 EP claimed
EP-4656642-A1 ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF GAN & LEE PHARM CO., LTD (CN) 2025-12-03 EP disclosed
EP-4647431-A1 COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR Gan & lee Pharm Co., Ltd. (CN) 2025-11-12 EP disclosed
US-12258328-B2 6-membered heteroaryl-containing aminopyridine compounds as EGFR inhibitors YUHAN CORPORATION (KR) 2025-03-25 US disclosed
US-20240400555-A1 Compounds, Compositions and Methods for Attenuation of Mammalian Translation of C-MYC or N-MYC Proteins of the MYC Proto-Oncogene Family of BHLH Transcription Factors INITIAL THERAPEUTICS, INC. (US) 2024-12-05 US disclosed
WO-2024226875-A2 COMPOUNDS, COMPOSITIONS AND METHODS FOR ATTENUATION OF MAMMALIAN TRANSLATION OF C-MYC OR N-MYC PROTEINS OF THE MYC PROTO-ONCOGENE FAMILY OF BHLH TRANSCRIPTION FACTORS INITIAL THERAPEUTICS, INC. (US) 2024-10-31 WO disclosed
US-12084445-B2 Broad-spectrum carbapenems VenatoRx Pharmaceuticals, Inc. (US) 2024-09-10 US disclosed
WO-2024156294-A1 ESTROGEN RECEPTOR PROTEOLYSIS TARGETING CHIMERA COMPOUND AND USE THEREOF 甘李药业股份有限公司 2024-08-02 WO disclosed
WO-2024146617-A1 COMPOUND AND METHOD FOR TARGETED DEGRADATION OF ANDROGEN RECEPTOR 甘李药业股份有限公司 2024-07-11 WO disclosed
EP-4392415-A1 SUBSTITUTED AMINOPYRIDINE COMPOUNDS AS EGFR INHIBITORS Yuhan Corporation (KR) 2024-07-03 EP disclosed
WO-2006058303-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-06-01 WO disclosed
US-20060106067-A1 Fused benzene derivative and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-05-18 US disclosed
US-20060079505-A1 Modulators of muscarinic receptors VERTEX PHARMACEUTICALS, INCORPORATED (US) 2006-04-13 US disclosed
EP-1636223-A1 BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS F. Hoffman-la Roche AG (CH) 2006-03-22 EP disclosed
WO-2006023852-A2 MODULATORS OF MUSCARINIC RECEPTORS VERTEX PHARMACEUTICALS, INCORPORATED (US) 2006-03-02 WO disclosed
CN-1688527-A Fused benzene derivatives and use TAKEDA CHEMICAL INDUSTRIES LTD (JP) 2005-10-26 CN disclosed
EP-1553074-A1 FUSED BENZENE DERIVATIVE AND USE Takeda Pharmaceutical Company Limited (JP) 2005-07-13 EP disclosed
WO-2005000842-A1 BENZOTHIAZOLE DERIVATIVES AS ADENOSINE RECEPTOR LIGANDS F. HOFFMAN-LA ROCHE AG (CH) 2005-01-06 WO disclosed
US-20040235915-A1 Benzothiazole derivatives F. HOFFMANN-LA ROCHE AG (CH) 2004-11-25 US disclosed